AICAR: AMPK Activator Research, Exercise Mimetic & Metabolic Studies

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is AICAR?

AICAR, or 5-aminoimidazole-4-carboxamide ribonucleotide, is a small molecule that functions as an adenosine analog and a key intermediate in the de novo purine biosynthesis pathway. Also known by the names acadesine and ZMP precursor, AICAR has become one of the most widely used pharmacological tools for studying AMP-activated protein kinase (AMPK) signaling in laboratory research. Its ability to mimic the effects of cellular energy depletion without requiring actual metabolic stress has made it indispensable in metabolic and exercise physiology research.

An important distinction should be made at the outset: AICAR is not a peptide. It is a nucleoside analog — a small molecule with a molecular weight of approximately 258.2 g/mol. However, AICAR appears in research peptide catalogs because it is studied alongside peptides and other bioactive compounds in overlapping research domains, including metabolic regulation, exercise physiology, and cellular energy sensing. Researchers investigating compounds like MOTS-c (a mitochondria-derived peptide that also activates AMPK) frequently work with AICAR as a pharmacological comparator or positive control for AMPK activation studies.

AICAR was first synthesized in the 1980s and entered widespread research use in the 1990s after its AMPK-activating properties were characterized. It gained significant public attention following the landmark 2008 publication by Narkar et al. in Cell, which demonstrated that AICAR administration improved running endurance by 44% in sedentary mice — earning it the designation of “exercise mimetic” and placing it at the center of a rapidly expanding field of metabolic research.

Mechanism of Action

AICAR’s mechanism of action centers on its intracellular conversion to ZMP (5-aminoimidazole-4-carboxamide ribonucleotide monophosphate), which mimics the effects of AMP on the cell’s master energy sensor, AMPK. Understanding this pathway is essential for interpreting the breadth of AICAR’s observed effects in research models.

Intracellular Conversion to ZMP

After entering cells via adenosine transporters, AICAR is phosphorylated by the enzyme adenosine kinase to form ZMP. This conversion is critical — AICAR itself has minimal biological activity, but ZMP is a structural analog of AMP (adenosine monophosphate) and binds to the gamma subunit of AMPK, allosterically activating the enzyme. ZMP also promotes AMPK activation by facilitating phosphorylation of the alpha subunit at threonine-172 by upstream kinases, primarily liver kinase B1 (LKB1).

AMPK — The Master Energy Sensor

AMPK is a heterotrimeric serine/threonine kinase composed of alpha (catalytic), beta, and gamma (regulatory) subunits. Under normal physiological conditions, AMPK is activated when the cellular AMP-to-ATP ratio rises — signaling that the cell is running low on energy. Once activated, AMPK orchestrates a comprehensive metabolic switch from anabolic (energy-consuming) to catabolic (energy-producing) processes. AICAR, through ZMP, activates this same switch without requiring actual energy depletion.

Downstream Effects of AMPK Activation

AMPK activation by AICAR triggers a cascade of downstream effects that have been extensively characterized in preclinical research:

• Increased fatty acid oxidation — AMPK phosphorylates and inhibits acetyl-CoA carboxylase (ACC), reducing malonyl-CoA levels and relieving inhibition of carnitine palmitoyltransferase 1 (CPT1). This allows increased transport and oxidation of fatty acids in mitochondria. This mechanism is central to AICAR’s observed effects on lipid metabolism in animal models.
• Enhanced glucose uptake — AMPK activation promotes translocation of GLUT4 glucose transporters to the cell membrane, particularly in skeletal muscle. This effect is insulin-independent, meaning it occurs through a separate signaling pathway from insulin-stimulated glucose uptake. This dual pathway activation has made AICAR a tool of significant interest in diabetes and insulin resistance research.
• Mitochondrial biogenesis — AMPK activates peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), a transcriptional coactivator that drives mitochondrial biogenesis. PGC-1α activation increases the expression of nuclear-encoded mitochondrial genes, leading to increased mitochondrial number and oxidative capacity over time. This pathway underlies many of the endurance-related observations in AICAR research.
• Inhibition of mTOR and protein synthesis — AMPK directly phosphorylates the tuberous sclerosis complex (TSC2), activating it as a negative regulator of mammalian target of rapamycin complex 1 (mTORC1). This inhibits protein synthesis and cell growth — shifting the cell away from growth and toward energy conservation and stress resistance.
• Autophagy induction — AMPK promotes autophagy through direct phosphorylation of ULK1 (Unc-51-like kinase 1) and through mTORC1 inhibition. Autophagy is the cell’s recycling mechanism for damaged organelles and misfolded proteins, and its role in cellular quality control has become a major area of research in aging and neurodegeneration.
• Anti-inflammatory signaling — AMPK activation has been associated with reduced NF-κB signaling and decreased production of pro-inflammatory cytokines in multiple cell types. This anti-inflammatory effect has been observed in macrophages, endothelial cells, and other immune-relevant cell populations treated with AICAR.

Research Applications

AICAR’s ability to pharmacologically activate AMPK has made it a cornerstone tool across multiple research disciplines. The following sections summarize the principal areas of investigation.

Exercise Physiology and the “Exercise Mimetic” Concept

The most widely cited AICAR study is the 2008 publication by Narkar et al. in Cell, conducted in Ronald Evans’ laboratory at the Salk Institute. In this study, sedentary mice treated with AICAR for four weeks demonstrated a 44% improvement in running endurance compared to untreated controls — without any exercise training. The treated mice showed metabolic adaptations resembling those induced by endurance exercise, including increased expression of oxidative metabolism genes and a shift toward slow-twitch (type I) muscle fiber characteristics.

This finding established the concept of pharmacological exercise mimesis and raised fundamental questions about the extent to which exercise adaptations can be reproduced through targeted pathway activation. Subsequent research has explored AICAR’s exercise-mimetic effects in combination with other compounds, including GW501516 (a PPAR-delta agonist), which produced synergistic effects on endurance when co-administered with AICAR in the Evans laboratory’s follow-up studies.

Researchers investigating exercise mimetics may also be interested in SLU-PP-332, an ERR (estrogen-related receptor) agonist that has demonstrated exercise-mimetic properties through a complementary mechanism — activating the transcriptional programs of exercise adaptation rather than the energy-sensing AMPK pathway.

Metabolic Syndrome and Diabetes Research

AICAR has been extensively studied in preclinical models of metabolic dysfunction. Key findings include:

• Insulin sensitivity: In rodent models of diet-induced obesity and type 2 diabetes, chronic AICAR administration has been observed to improve insulin sensitivity and glucose tolerance. The insulin-independent GLUT4 translocation mechanism provides a rationale for glucose-lowering effects even in the context of insulin resistance.
• Hepatic glucose output: AICAR treatment has been shown to suppress hepatic gluconeogenesis in animal models, reducing liver glucose production. AMPK activation inhibits transcription factors that drive gluconeogenic gene expression, including CREB-regulated transcription coactivator 2 (CRTC2).
• Lipid metabolism: Studies in obese rodent models have reported reductions in plasma triglycerides, hepatic lipid accumulation, and adipose tissue mass following AICAR treatment. These effects are attributed to increased fatty acid oxidation and decreased lipogenesis via ACC inhibition.

Cardiac Ischemia-Reperfusion Research

AICAR (under the name acadesine) was investigated in the most advanced clinical context of any AMPK activator. Phase 2 clinical trials in the 1990s evaluated acadesine for reducing adverse cardiac events during coronary artery bypass graft (CABG) surgery. The rationale was that AMPK activation during ischemia could shift cardiac metabolism toward more efficient substrate utilization and reduce reperfusion injury.

Early trials showed promising signals — a meta-analysis of Phase 2 data suggested reduced incidence of myocardial infarction in acadesine-treated patients. However, a subsequent Phase 3 trial (the RED-CABG trial) was halted due to futility after an interim analysis showed insufficient efficacy to meet its primary endpoint of reducing all-cause mortality. The discontinuation of RED-CABG remains the largest clinical setback in AICAR’s research history, though the trial did contribute valuable safety data on AICAR administration in humans.

Cancer Research

The relationship between AMPK activation and cancer biology is complex and context-dependent. AICAR has been investigated in cancer research through several lenses:

• Tumor suppression via mTOR inhibition: Because AMPK activation inhibits mTORC1, AICAR has been studied as a potential inhibitor of tumor cell proliferation. In vitro studies have demonstrated growth inhibition in multiple cancer cell lines, including hepatocellular carcinoma, breast cancer, and prostate cancer cells.
• Metabolic vulnerability: Some cancer cells exhibit altered AMPK signaling or increased dependence on specific metabolic pathways. AICAR-mediated AMPK activation can disrupt these metabolic adaptations, making certain cancer types potentially vulnerable to AMPK agonists.
• Limitations and caveats: Not all cancer research has shown anti-tumor effects with AICAR. Some studies have suggested that AMPK activation may be protective for cancer cells under metabolic stress, enabling survival under nutrient-poor conditions. The context-dependent nature of AMPK in cancer — sometimes tumor-suppressive, sometimes tumor-promoting — remains an active area of investigation.

Neurodegeneration Research

AMPK activation by AICAR has been explored in models of neurodegenerative disease. Research has investigated AICAR’s effects on autophagy-mediated clearance of protein aggregates (relevant to Alzheimer’s and Parkinson’s disease models), neuroinflammation, and mitochondrial quality control in neurons. Studies in rodent models have reported improvements in cognitive function markers and reductions in neuroinflammatory markers following AICAR treatment, though the blood-brain barrier penetration of AICAR and the role of AMPK in neuronal versus glial cells are areas requiring further investigation.

Researchers studying mitochondrial pathways in neurodegeneration may find complementary data in MOTS-c research, as this mitochondria-derived peptide shares the AMPK activation pathway while operating through a distinct upstream mechanism.

Dosing in Research Models

The following table summarizes dosing ranges that have been reported in published preclinical and clinical research. These values are provided as reference points for the scientific literature and are not recommendations for any application.

Model	Route	Dose Range	Duration	Research Context
Mouse (in vivo)	Subcutaneous	250–500 mg/kg/day	4–8 weeks	Exercise mimetic / endurance studies
Rat (in vivo)	Intraperitoneal	100–500 mg/kg/day	1–8 weeks	Metabolic studies / diabetes models
Rat (in vivo)	Intravenous	1–10 mg/kg bolus	Acute	Cardiac ischemia-reperfusion
Cell culture (in vitro)	Media addition	0.5–2 mM	1–72 hours	AMPK activation assays
Human (clinical trials)	Intravenous infusion	0.1 mg/kg/min (continuous)	7–24 hours perioperative	Acadesine cardiac surgery trials

Important notes on dosing: The high doses used in rodent models (particularly the 500 mg/kg range) reflect the pharmacokinetics of AICAR in mice and cannot be directly extrapolated to other species through simple body weight scaling. Allometric scaling, differences in ZMP clearance rates, and species-specific adenosine kinase activity all affect dose translation. Researchers should consult species-specific pharmacokinetic literature when designing protocols.

Reconstitution and Handling

AICAR is typically supplied as a lyophilized (freeze-dried) powder. Proper handling and reconstitution are essential for maintaining compound integrity in research applications.

Reconstitution Protocol

• Solvent: AICAR is freely soluble in water and aqueous buffers. Reconstitution in sterile water or phosphate-buffered saline (PBS) is standard practice. For in vitro applications, reconstitution in cell culture-grade DMSO is also common, followed by dilution into aqueous media to the desired working concentration.
• Concentration: Stock solutions of 50–100 mM in water or 100–250 mM in DMSO are typical for in vitro work. For in vivo applications, concentrations are adjusted based on the injection volume appropriate for the animal model.
• Filtration: Solutions intended for in vivo use should be sterile-filtered through a 0.22 μm membrane filter after reconstitution.

Storage Conditions

• Lyophilized powder: Store at −20°C, protected from light and moisture. Under these conditions, AICAR is stable for 24 months or longer.
• Reconstituted solution (aqueous): Store at −20°C in single-use aliquots. Aqueous solutions are stable for approximately 1–3 months at −20°C. Avoid repeated freeze-thaw cycles.
• Reconstituted solution (DMSO): Store at −20°C. DMSO stocks are generally more stable than aqueous solutions and can remain viable for 3–6 months when properly stored.
• Working dilutions: Prepare fresh on the day of use. Do not store working-concentration dilutions.

Stability Considerations

AICAR is relatively stable compared to many peptide compounds, owing to its small-molecule nucleoside structure. However, prolonged exposure to elevated temperatures, repeated freeze-thaw cycles, and extreme pH conditions can degrade the compound. Researchers should verify compound integrity by HPLC or mass spectrometry if storage conditions have been compromised.

Safety Profile

AICAR’s safety profile has been characterized more extensively than many research compounds, primarily because of the acadesine clinical trial program conducted in the 1990s. However, significant gaps remain in the long-term safety data.

Clinical Trial Safety Data

The acadesine cardiac surgery trials (Phase 2 and Phase 3) enrolled over 4,000 patients receiving intravenous acadesine or placebo. The most commonly reported adverse events in these trials included:

• Transient hyperuricemia (elevated uric acid levels) — the most frequently noted metabolic effect, attributable to AICAR’s metabolism through the purine degradation pathway
• Mild, reversible increases in serum creatinine in some patients
• Hypoglycemia (low blood sugar) — consistent with AICAR’s mechanism of increasing glucose uptake
• No excess mortality was observed in acadesine-treated groups compared to placebo in the Phase 3 RED-CABG trial

Preclinical Safety Observations

In animal models, the following safety-related observations have been reported:

• Hyperuricemia: Consistent with human data, elevated uric acid is the most common metabolic consequence of AICAR administration in animal models. ZMP is eventually degraded through the purine catabolic pathway, producing uric acid as an end product.
• Hypoglycemia risk: At higher doses, AICAR-mediated glucose uptake can produce significant drops in blood glucose. This effect requires monitoring in research protocols, particularly in fasted animals or models with compromised gluconeogenesis.
• Lactic acidosis: High-dose AICAR has been associated with lactic acidosis in some animal studies, likely related to shifts in metabolic substrate utilization at supraphysiological levels of AMPK activation.
• Cardiac effects: Because AICAR is an adenosine analog, it can interact with adenosine receptors at high concentrations, potentially producing bradycardia or other cardiac effects. These receptor-mediated effects are distinct from AICAR’s AMPK-activating mechanism.

WADA Prohibited Status

The World Anti-Doping Agency (WADA) added AICAR to its Prohibited List in 2009, classifying it under Section S4 (Hormone and Metabolic Modulators). This prohibition followed the publication of the Evans laboratory exercise-mimetic data and reflects concern that AICAR could be used to enhance athletic performance through pharmacological activation of endurance pathways. AICAR remains prohibited at all times (both in-competition and out-of-competition) under WADA regulations, and athletes subject to anti-doping testing risk sanctions for AICAR use.

Limitations of Available Safety Data

Despite the relatively large clinical trial database, several important safety questions remain unanswered:

• Long-term effects of chronic AICAR administration have not been studied in humans
• The clinical trial population (cardiac surgery patients) may not reflect the safety profile in other populations
• Interactions with other pharmacological agents have not been systematically characterized
• The effects of chronic AMPK activation on immune function, reproductive biology, and developmental processes have not been comprehensively evaluated

Frequently Asked Questions

Is AICAR a peptide?

No. AICAR is a nucleoside analog — a small molecule with a molecular weight of approximately 258.2 g/mol. It contains no amino acids and no peptide bonds. It appears in research peptide catalogs because it is studied in overlapping research contexts with bioactive peptides, particularly in metabolic regulation and exercise physiology.

How does AICAR activate AMPK?

AICAR enters cells via adenosine transporters and is phosphorylated by adenosine kinase to form ZMP. ZMP is a structural analog of AMP and binds to the gamma subunit of AMPK, allosterically activating the enzyme and promoting its phosphorylation by upstream kinase LKB1. This mimics the effects of cellular energy depletion without requiring actual metabolic stress.

What is the difference between AICAR and exercise at the molecular level?

Exercise activates AMPK through genuine energy depletion — ATP consumption during muscle contraction raises the AMP/ATP ratio. AICAR bypasses the need for energy depletion by providing ZMP, which mimics AMP. However, exercise activates many additional pathways beyond AMPK, including calcium-dependent signaling (CaMKII), mechanical stress responses, and hormonal cascades. AICAR activates a subset of the exercise-induced signaling network, which is why it is described as a partial exercise mimetic.

Why was the acadesine Phase 3 trial halted?

The RED-CABG (Reduction in Cardiovascular Events by Acadesine in Patients Undergoing CABG) Phase 3 trial was stopped after an interim futility analysis determined that the trial was unlikely to meet its primary endpoint of reducing all-cause mortality. The halt was not due to safety concerns — no excess adverse events were observed in the treatment group compared to placebo.

How does AICAR compare to MOTS-c for AMPK activation?

MOTS-c is a mitochondria-derived peptide that activates AMPK through a different upstream mechanism — it inhibits the folate cycle and de novo purine biosynthesis, leading to accumulation of endogenous AICAR (ZMP) within cells. In effect, MOTS-c produces AMPK activation indirectly by increasing the cell’s own ZMP levels, while exogenous AICAR provides ZMP directly. Both converge on AMPK, but the upstream biology and additional pathway effects differ substantially.

---

Summary

AICAR occupies a unique position in metabolic research as one of the most well-characterized pharmacological activators of AMPK, the cell’s master energy-sensing kinase. Through its intracellular conversion to ZMP, AICAR mimics the effects of cellular energy depletion, triggering a comprehensive metabolic shift toward fatty acid oxidation, glucose uptake, mitochondrial biogenesis, and autophagy — while simultaneously suppressing energy-consuming processes like protein synthesis and lipogenesis.

The 2008 demonstration that AICAR could improve running endurance by 44% in sedentary mice established the exercise-mimetic concept and remains one of the most influential findings in metabolic pharmacology. Subsequent research has expanded AICAR’s investigational profile into metabolic syndrome, diabetes, cardiac ischemia-reperfusion, cancer biology, and neurodegeneration, with the common thread being the central role of AMPK in each of these research domains.

AICAR’s progression into Phase 3 clinical trials (as acadesine for cardiac surgery) provided a body of human safety data unusual for a research compound of this type, though the trial’s discontinuation for futility highlighted the challenges of translating preclinical AMPK activation into clinical outcomes. The compound’s WADA prohibition since 2009 reflects its recognized potential to influence exercise-relevant physiological pathways.

For researchers working in AMPK biology, metabolic regulation, or exercise physiology, AICAR remains an essential pharmacological tool. Its mechanism of action is well-defined, its downstream effects are extensively characterized, and its role as a benchmark AMPK activator ensures its continued relevance in basic and translational research.

Explore NorthPeptide’s catalog of research compounds including AICAR, SLU-PP-332, and MOTS-c for metabolic and exercise physiology research.

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Višnjić et al.	2021	Systematic Review	AICAr AMPK-dependent and AMPK-independent effects	PMC8147799
Narkar et al.	2008	Research	AMPK and PPARδ agonists as exercise mimetics	PMC2706130
Smith et al.	2005	Research	AMPK activation increases fatty acid oxidation in muscle	PMC1464526
Guerrieri et al.	2015	Research	Exercise-mimetic AICAR transiently benefits brain function	PMC4621892
Viscomi et al.	2011	Research	Sustained AMPK activation improves muscle function	PMC5179920
Zhao et al.	2025	Research	AICAR prevents diabetic polyneuropathy via mitophagy	PMC11720447
Canto et al.	2021	Research	AMPK activator O304 improves metabolic and cardiac function	PMC8602430